JP2011528371A5 - - Google Patents

Download PDF

Info

Publication number
JP2011528371A5
JP2011528371A5 JP2011518897A JP2011518897A JP2011528371A5 JP 2011528371 A5 JP2011528371 A5 JP 2011528371A5 JP 2011518897 A JP2011518897 A JP 2011518897A JP 2011518897 A JP2011518897 A JP 2011518897A JP 2011528371 A5 JP2011528371 A5 JP 2011528371A5
Authority
JP
Japan
Prior art keywords
composition
item
immunogenic
particle
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011518897A
Other languages
English (en)
Japanese (ja)
Other versions
JP5781929B2 (ja
JP2011528371A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/050764 external-priority patent/WO2010009277A2/en
Publication of JP2011528371A publication Critical patent/JP2011528371A/ja
Publication of JP2011528371A5 publication Critical patent/JP2011528371A5/ja
Application granted granted Critical
Publication of JP5781929B2 publication Critical patent/JP5781929B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011518897A 2008-07-15 2009-07-15 免疫原性の両親媒性ペプチド組成物 Expired - Fee Related JP5781929B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8094208P 2008-07-15 2008-07-15
US61/080,942 2008-07-15
PCT/US2009/050764 WO2010009277A2 (en) 2008-07-15 2009-07-15 Immunogenic amphipathic peptide compositions

Publications (3)

Publication Number Publication Date
JP2011528371A JP2011528371A (ja) 2011-11-17
JP2011528371A5 true JP2011528371A5 (https=) 2012-08-30
JP5781929B2 JP5781929B2 (ja) 2015-09-24

Family

ID=41478598

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011518897A Expired - Fee Related JP5781929B2 (ja) 2008-07-15 2009-07-15 免疫原性の両親媒性ペプチド組成物

Country Status (5)

Country Link
US (1) US20110250237A1 (https=)
EP (1) EP2313085A2 (https=)
JP (1) JP5781929B2 (https=)
CA (1) CA2730737A1 (https=)
WO (1) WO2010009277A2 (https=)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
US20100015171A1 (en) * 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
JP5867952B2 (ja) * 2009-06-10 2016-02-24 ノバルティス アーゲー ベンゾナフチリジン含有ワクチン
CA2768186A1 (en) 2009-07-15 2011-01-20 Novartis Ag Rsv f protein compositions and methods for making same
EP2558069A1 (en) 2010-04-13 2013-02-20 Novartis AG Benzonapthyridine compositions and uses thereof
NZ606591A (en) 2010-07-06 2015-02-27 Novartis Ag Cationic oil-in-water emulsions
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2625189B1 (en) 2010-10-01 2018-06-27 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
US9327021B2 (en) * 2010-11-15 2016-05-03 Sanofi Pasteur Limited Immunogenic compositions
WO2012089231A1 (en) 2010-12-30 2012-07-05 Okairòs Ag Paramyxovirus vaccines
WO2012129483A1 (en) 2011-03-24 2012-09-27 Novartis Ag Adjuvant nanoemulsions with phospholipids
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
CA2835644C (en) 2011-05-13 2021-06-15 Novartis Ag Pre-fusion rsv f antigens
RU2013154295A (ru) 2011-06-08 2015-07-20 Шир Хьюман Дженетик Терапис, Инк. КОМПОЗИЦИИ ЛИПИДНЫХ НАНОЧАСТИЦ И СПОСОБЫ ДЛЯ ДОСТАВКИ мРНК
JP6059220B2 (ja) 2011-07-06 2017-01-18 ノバルティス アーゲー 核酸を含む水中油型エマルジョン
MX350258B (es) 2011-07-06 2017-08-31 Novartis Ag Emulsiones cationicas de aceite en agua.
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2014016152A1 (en) 2012-07-27 2014-01-30 Institut National De La Sante Et De La Recherche Medicale Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
WO2014028429A2 (en) 2012-08-14 2014-02-20 Moderna Therapeutics, Inc. Enzymes and polymerases for the synthesis of rna
NZ630542A (en) 2012-08-16 2017-06-30 Ipierian Inc Methods of treating a tauopathy
US20140141037A1 (en) * 2012-11-20 2014-05-22 Novartis Ag Rsv f prefusion trimers
EP2922570A1 (en) 2012-11-20 2015-09-30 GlaxoSmithKline Biologicals SA Rsv f prefusion trimers
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
EP2968391A1 (en) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
CA2906770A1 (en) * 2013-03-15 2014-09-18 Vlp Biotech, Inc. Palivizumab epitope-based virus-like particles
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
JP2017512751A (ja) 2014-02-14 2017-05-25 アイピエリアン，インコーポレイティド タウペプチド、抗タウ抗体、およびそれらの使用方法
PL4023249T3 (pl) 2014-04-23 2025-03-10 Modernatx, Inc. Szczepionki z kwasem nukleinowym
EP2974739A1 (en) 2014-07-15 2016-01-20 Novartis AG RSVF trimerization domains
MX384992B (es) 2014-06-13 2025-03-14 Glaxosmithkline Biologicals Sa Combinaciones inmunógenas.
US20170204152A1 (en) 2014-07-16 2017-07-20 Moderna Therapeutics, Inc. Chimeric polynucleotides
AU2015326407C1 (en) * 2014-10-03 2021-06-24 Engeneic Molecular Delivery Pty Ltd Enhanced loading of intact, bacterially derived vesicles with small molecule compounds
EP3031822A1 (en) * 2014-12-08 2016-06-15 Novartis AG Cytomegalovirus antigens
CN107106668A (zh) * 2014-12-10 2017-08-29 华西亚生医有限公司 用于免疫中的有效抗体生产的新颖蛋白质结构
JP2018516847A (ja) * 2015-03-25 2018-06-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 生体高分子薬を送達するための組成物及び方法
EP3359670B2 (en) 2015-10-05 2024-02-14 ModernaTX, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
US12257352B2 (en) 2016-06-20 2025-03-25 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
CN115427078A (zh) * 2018-07-30 2022-12-02 刘扶东 凝聚复合物的治疗性纳米粒子及其治疗细菌的用途
KR102184153B1 (ko) * 2019-02-25 2020-11-30 부산대학교 산학협력단 고분자 지지체 기반의 인플루엔자 바이러스 유사 구조체 및 이의 제조방법
WO2020198020A1 (en) * 2019-03-22 2020-10-01 Kansas State University Research Foundation Lipid encasing amphipathic peptides
MX2022002980A (es) 2019-09-16 2022-04-06 Amgen Inc Metodo para la esterilizacion externa de un dispositivo de suministro de farmacos.
AU2021367917A1 (en) * 2020-10-28 2023-06-22 Sanofi Pasteur Liposomes containing tlr4 agonist, preparation and uses thereof
WO2022103927A1 (en) * 2020-11-12 2022-05-19 Shape Biopharmaceuticals Inc. Immunogenic compositions for coronaviruses
US20240279313A1 (en) * 2021-08-11 2024-08-22 The Regents Of The University Of California Barrier function preserving peptides for membranes
WO2025242657A1 (en) 2024-05-21 2025-11-27 Shape Biopharmaceuticals Ag Lipopeptide building blocks and aggregates

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0749376B2 (ja) * 1988-12-16 1995-05-31 アルバニー メディカル カレジ 免疫原性組成物および医薬組成物
WO1997038010A2 (en) * 1996-04-11 1997-10-16 The University Of British Columbia Fusogenic liposomes
US7208314B2 (en) * 2002-02-26 2007-04-24 Mirus Bio Corporation Compositions and methods for drug delivery using pH sensitive molecules
TWI433693B (zh) * 2003-02-14 2014-04-11 Childrens Hosp & Res Ct Oak 親脂藥物傳送媒介物及其使用方法
AU2004283078A1 (en) * 2003-10-01 2005-05-06 Children's Hospital & Research Center At Oakland Lipophilic drug delivery vehicle and methods of use thereof
WO2007145659A1 (en) * 2005-11-10 2007-12-21 The Regents Of The University Of California Synthetic ldl as targeted drug delivery vehicle

Similar Documents

Publication Publication Date Title
JP2011528371A5 (https=)
JP4294584B2 (ja) 核酸ワクチン接種の免疫応答を高めるための方法
DK2729127T3 (en) METHODS FOR LIPOSOMES PREPARATION
US20170307612A1 (en) Kit for detecting virus
JP2016504312A5 (https=)
Atmar et al. Adjuvants for pandemic influenza vaccines
Carmona-Ribeiro et al. Cationic nanostructures for vaccines design
EA017887B1 (ru) Полимерные мультиэпитопные вакцины против гриппа
JP6119030B2 (ja) インフルエンザを治療するための組成物及び方法
JP4634997B2 (ja) ウィロソーム様粒子
TW201427686A (zh) 改良之疫苗組成物及使用方法
JP7409594B2 (ja) 医薬組成物、規定のサイズの脂質ベシクル粒子を使用する調製物のための方法、及びそれらの使用
MX2011002267A (es) Vacuna.
WO2007132790A1 (ja) 細菌菌体成分を含む脂質膜を有するリポソーム
CN111565706A (zh) 药物组合物、包括脂质囊泡颗粒尺寸设定的制备方法及其用途
CN103002908B (zh) 粘膜疫苗
Jalilian et al. Properties and prospects of adjuvants in influenza vaccination-messy precipitates or blessed opportunities?
US20240366747A1 (en) Universal vaccine for influenza virus based on tetrameric m2 protein incorporated into nanodiscs
JPH08506592A (ja) ３−ｏ−脱アシル化モノホスホリル脂質Ａ含有のインフルエンザワクチン組成物
US10426828B2 (en) Compositions of multimeric-multiepitope influenza polypeptides and their production
TW201217000A (en) Vaccine compositions based on sticholysin encapsulated into liposomes
CN103282049B (zh) 免疫原性组合物
KR20110061611A (ko) 백신 보조제 조합
US12006350B2 (en) Triblock peptide amphiphiles, micelles and methods of use
Mendoza‐Ramírez et al. Silica Nanoparticles as Multifunctional Platforms for Vaccine Delivery and Immune Modulation in Infectious Diseases